TNF-muteins
US5486463A · kind A · utility
12Cited by
1References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 1, 1993 |
| Grant date | Jan 23, 1996 |
| Priority date | — |
| Expiry date | Apr 1, 2013 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to a human Tumor Necrosis Factor mutein or a pharmaceutically acceptable salt thereof having selective binding affinity for the human p55-Tumor-Necrosis-Factor-Receptor characterized in that the amino acid sequence of human Tumor Necrosis Factor is changed at least at position 86 having a threonine instead of a serine residue, a DNA sequence coding for such a mutein, a vector comprising such a DNA sequence, and a host cell transformed by such a vector.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.